SCHEMBL185193

SCHEMBL185193

COC(=O)Cc1ccc(Oc2cnc(N)s2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.44
MMP9 P14780 1/20 0.44
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
GAA P10253 1/20 0.43
GFER P55789 1/20 0.43
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TP53 P04637 1/20 0.38
MBOAT4 Q96T53 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19937712 0.85 SLC7A5 (0.43) ALDH1A1NPC1RAB9APOLBGAA
SCHEMBL184607 0.80 MAPT (0.47) ALDH1A1NPC1RAB9ALMNAPOLB
SCHEMBL12475998 0.76 TSHR (0.54) ALDH1A1NPC1RAB9ALMNAPOLB
SCHEMBL12476000 0.76 POLB (0.42) ALDH1A1NPC1RAB9ALMNAPOLB
SCHEMBL3142591 0.75 KDM4E (0.52) ALDH1A1NPC1RAB9ALMNAPOLB
SCHEMBL9071240 0.74 ALDH1A1 (0.39) ALDH1A1NPC1RAB9ALMNAPOLB
SCHEMBL2655449 0.74 TEAD4 (0.47) ALDH1A1NPC1RAB9ALMNAPOLB
SCHEMBL1636834 0.72 SMN1; SMN2 (0.71) ALDH1A1POLBGAAGFERHTT
SCHEMBL23582116 0.72 RAB9A (0.46) ALDH1A1NPC1RAB9ALMNAMMP9
SCHEMBL11972292 0.72 TP53 (0.44) ALDH1A1NPC1RAB9ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
EP-2402327-A1 Acetamide compounds as glucokinase activators, their process and medicinal applications Advinus Therapeutics Private Limited (IN) 2012-01-04 EP disclosed
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100310493-A1 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION GCK, GCKR, ALDOA ALDH1A1 843/4885NPC1 3362/4885RAB9A 3140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.